Tau Therapy Shows Continued Benefit at 2 Years in Alzheimer's
Biogen said the 60-milligram dose also improved five of six cognition and function measures and caused mostly mild side effects.
- On Tuesday, Biogen presented trial data showing its 60-mg experimental drug dose slowed cognitive decline in early Alzheimer's patients by 38% after two years.
- Current amyloid-targeting drugs like Leqembi and Eli Lilly's Kisunla slow cognitive decline by 25% to 30%, while the experimental drug targets tau proteins developed with Ionis Pharmaceuticals.
- Biogen's head of clinical development Diana Gallagher said the 60-mg dose is easier to tolerate than 115-mg regimens, with patients showing improvements in five of six cognition and function measures.
- The improvement corresponds to a more than 1-point gain on the Clinical Dementia Rating-Sum of Boxes, which Gallagher called "highly clinically meaningful," with no reports of dangerous brain swelling.
- Biogen is discussing Phase 3 trial outlines with regulators, though results for the experimental drug remain several years away, according to Gallagher.
16 Articles
16 Articles
Tau Therapy Shows Continued Benefit at 2 Years in Alzheimer's
(MedPage Today) -- Diranersen, an investigational antisense oligonucleotide therapy that targets tau, continued to show benefits for 96 weeks, data from the open-label extension of the phase II CELIA trial suggested. At 2 years, diranersen continued...
Biogen's tau-targeting Alzheimer's drug showed 38% slower decline after two years—but the data weren't randomized
Biogen reported that experimental tau-lowering drug diranersen slowed decline by 38% after two years in a low-dose group, but the open-label findings are not randomized or approved treatment evidence.
Biogen's anti-tau Alzheimer's drug benefits increase at 2 years
Biogen’s Diranersen Demonstrates Increasing Clinical Benefit at Two Years in Early Alzheimer’s Disease
Diranersen slowed clinical decline by 38% on CDR-SB at two years (Week 96) with the 60 mg twice-yearly regimen, corresponding to a 1.09-point treatment differenceGreater slowing of clinical decline across 5 of 6 measures at two years compared with 18…
Coverage Details
Bias Distribution
- 40% of the sources lean Left, 40% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
















